Sandra M. Herrmann

10.3k total citations
168 papers, 5.9k citations indexed

About

Sandra M. Herrmann is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Sandra M. Herrmann has authored 168 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 54 papers in Pulmonary and Respiratory Medicine, 40 papers in Molecular Biology and 39 papers in Oncology. Recurrent topics in Sandra M. Herrmann's work include Renal and Vascular Pathologies (27 papers), Renal Diseases and Glomerulopathies (17 papers) and Renal cell carcinoma treatment (16 papers). Sandra M. Herrmann is often cited by papers focused on Renal and Vascular Pathologies (27 papers), Renal Diseases and Glomerulopathies (17 papers) and Renal cell carcinoma treatment (16 papers). Sandra M. Herrmann collaborates with scholars based in United States, Germany and China. Sandra M. Herrmann's co-authors include Lilach O. Lerman, Amir Lerman, Stephen C. Textor, Ahmed Saad, Joerg Herrmann, Sandhya Manohar, Alfonso Eirin, Claudio Napoli, Nelson Leung and Rhian M. Touyz and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Sandra M. Herrmann

155 papers receiving 5.8k citations

Peers

Sandra M. Herrmann
Comparison fields: 5 of 152
  • Molecular Biology 1.8k
  • Surgery 1.3k
  • Pulmonary and Respiratory Medicine 1.2k
  • Oncology 960
  • Cardiology and Cardiovascular Medicine 946
David S. Geller United States
Theodore M. Danoff United States
Wim J. Sluiter Netherlands
О. Л. Барбараш Russia
Hirokazu Okada Japan
Keiichi Ito Japan
Zamaneh Kassiri Canada
Solbritt Rantapää‐Dahlqvist Sweden
Toshiharu Ishii Japan
Andrew I. Schafer United States
David S. Geller United States View profile →
Citations per field, relative to Sandra M. Herrmann
Sandra M. Herrmann · 1×
Citations per year, relative to Sandra M. Herrmann
Sandra M. Herrmann · 1×

Countries citing papers authored by Sandra M. Herrmann

Since Specialization
Citations

This map shows the geographic impact of Sandra M. Herrmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra M. Herrmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra M. Herrmann more than expected).

Fields of papers citing papers by Sandra M. Herrmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra M. Herrmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra M. Herrmann. The network helps show where Sandra M. Herrmann may publish in the future.

Co-authorship network of co-authors of Sandra M. Herrmann

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra M. Herrmann. A scholar is included among the top collaborators of Sandra M. Herrmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra M. Herrmann. Sandra M. Herrmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Title Journal Authors Indexed citations
1 Diagnostic and Prognostic Value of High‐Sensitivity Troponin T for Cardiovascular Outcomes in Patients Receiving Immune Checkpoint Inhibitor Therapy Journal of the American Heart Association Juan Farina, Kamal Awad et al. 1
2 Update on the Assessment of GFR in Patients with Cancer Kidney360 Verônica T. Costa e Silva, Fei Xiong et al. 0
3 WCN25-1014 TECLISTAMAB AND NIVOLUMAB: A SYNERGISTIC KIDNEY STORM - A CASE OF ACUTE INTERSTITIAL NEPHRITIS WITH DUAL IMMUNOTHERAPY Kidney International Reports Sandra M. Herrmann et al. 0
4 Biomarker-guided infliximab therapy for immune checkpoint inhibitor-induced acute interstitial nephritis Nephrology Dialysis Transplantation John C. Lieske, Sandra M. Herrmann et al. 1
5 The impact of peptide receptor radionucleotide therapy with Lutetium-177 DOTATATE on cardiac metastases in neuroendocrine tumors European Heart Journal Isabel G. Scalia, M.L. González Pereyra et al. 0
6 Incidence of acute kidney injury in patients with relapsed and refractory multiple myeloma treated with teclistamab vs chimeric antigen receptor T-cell therapy. Journal of Clinical Oncology Lisa E. Vaughan, Yi Lin et al. 2
7 Diagnosis and management of immune checkpoint inhibitor–associated nephrotoxicity: a position statement from the American Society of Onco-nephrology Kidney International Sandra M. Herrmann, Ala Abudayyeh et al. 12
8 Rechallenge With High-Dose Methotrexate After Treatment With Glucarpidase in Adult Patients With Lymphoma JCO Oncology Practice Jason N. Barreto, Kristin C. Mara et al. 4
9 Management of hypertension in patients with cancer: challenges and considerations Clinical Kidney Journal Shubhi Pandey, Kenar D. Jhaveri et al. 10
10 Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis Journal for ImmunoTherapy of Cancer Meghan E. Sise, Qiyu Wang et al. 23
11 Differences in Anthropometric Parameters of Children in Six European Countries Children Semánová Csilla, Gergő József Szöllösi et al. 0
12 Unusual Course of Paraneoplastic IgA Nephropathy Associated With Squamous Cell Lung Cancer Journal of the American Society of Nephrology Pingchuan Zhang, Sandra M. Herrmann et al. 0
13 Successful Treatment of Pembrolizumab-Induced Severe Capillary Leak Syndrome and Lymphatic Capillary Dysfunction SHILAP Revista de lepidopterología Sandra M. Herrmann, Nelson Leung et al. 16
14 A Systematic Review and Meta-Analysis of Cell-Based Interventions in Experimental Diabetic Kidney Disease Stem Cells Translational Medicine LaTonya J. Hickson, Xiaohui Bian et al. 36
15 Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A single‐center analysis Cancer Lisa E. Vaughan, Collin M. Costello et al. 27
16 Senescence marker activin A is increased in human diabetic kidney disease: association with kidney function and potential implications for therapy BMJ Open Diabetes Research & Care Xiaohui Bian, Tomás P. Griffin et al. 44
17 Child-centred educational practice in different early education settings: Associations with professionals’ attitudes, self-efficacy, and professional background Early Childhood Research Quarterly Sonja Perren, Sandra M. Herrmann et al. 58
18 Biomarkers of Kidney Injury and Klotho in Patients with Atherosclerotic Renovascular Disease Clinical Journal of the American Society of Nephrology Moo Yong Park, Sandra M. Herrmann et al. 37
19 Primary Proteasome Inhibition Results in Cardiac Dysfunction European Journal of Heart Failure Sandra M. Herrmann, Ardan M. Saguner et al. 61
20 Chronic Proteasome Inhibition Contributes to Coronary Atherosclerosis Circulation Research Sandra M. Herrmann, Ardan M. Saguner et al. 86

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by David S. Geller Breakdown of academic impact, for papers by Theodore M. Danoff Breakdown of academic impact, for papers by Wim J. Sluiter Breakdown of academic impact, for papers by О. Л. Барбараш Breakdown of academic impact, for papers by Hirokazu Okada Breakdown of academic impact, for papers by Keiichi Ito Breakdown of academic impact, for papers by Zamaneh Kassiri Breakdown of academic impact, for papers by Solbritt Rantapää‐Dahlqvist Breakdown of academic impact, for papers by Toshiharu Ishii Breakdown of academic impact, for papers by Andrew I. Schafer
Rankless by CCL
2026